Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CEL SCI CORPCVM · Entity 7495 | Senior Vice President | September 30, 2022 | October 03, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CEL SCI CORP
Report date September 30, 2022 · Filed October 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 120,226 |
Reported balance
After 2022-09-30 transaction · row 1
1 source rowRow 1 · 2022-09-30 · Grant · Acquired 1,266 · Balance 120,226 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2022 Filed Oct 3, 2022 11:23 UTC | CEL SCI CORP CVM · Entity 7495 | GrantCommon Stock | 1,266 | $3.09 | $3,911.94 |
DisclosureSEC source: 0001236215-22-000008 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,226 Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 13:22 UTC | CEL SCI CORP CVM · Entity 7495 | GrantCommon Stock | 876 | $4.50 | $3,942.00 |
DisclosureSEC source: 0001236215-22-000004 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,960 Read SEC document |
| June 13, 2022 Filed Jun 14, 2022 21:24 UTC | CEL SCI CORP CVM · Entity 7495 | GrantOptions · Derivative | 80,000 | $0.01 Strike: $3.35 | $800.00 |
DisclosureSEC source: 0001236030-22-000013 · primary_doc.xml · derivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 832,353 Underlying: Common Stock · 80,000 shares Expires 2032-06-12 F1 · derivative.exercise_date: The stock options vest in three (3) equal annual installments commencing one year after the grant date. Read SEC document |
| March 31, 2022 Filed Mar 31, 2022 20:56 UTC | CEL SCI CORP CVM · Entity 7495 | GrantCommon Stock | 1,006 | $3.93 | $3,953.58 |
DisclosureSEC source: 0001236030-22-000008 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,084 Read SEC document |
| December 31, 2021 Filed Jan 3, 2022 15:14 UTC | CEL SCI CORP CVM · Entity 7495 | GrantCommon Stock | 557 | $7.10 | $3,954.70 |
DisclosureSEC source: 0001236030-22-000004 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,078 Read SEC document |
| November 19, 2021 Filed Nov 29, 2021 14:29 UTC | CEL SCI CORP CVM · Entity 7495 | GrantOptions · Derivative | 50,000 | $0.01 Strike: $10.48 | $500.00 |
DisclosureSEC source: 0001236215-21-000014 · primary_doc.xml · derivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 753,253 Underlying: Common Stock · 50,000 shares Expires 2031-11-18 F1 · derivative.exercise_date: Each option entitles the holder to purchase one share of the Company's common stock at a price of $10.48 per share. The stock options vest 100% upon the approval of the first marketing application for any pharmaceutical based upon the Company's Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia. None of the options will be exercisable before November 19, 2022. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 13:13 UTC | CEL SCI CORP CVM · Entity 7495 | GrantCommon Stock | 343 | $10.99 | $3,769.57 |
DisclosureSEC source: 0001236030-21-000006 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,521 Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 13:12 UTC | CEL SCI CORP CVM · Entity 7495 | GrantCommon Stock | 435 | $8.68 | $3,775.80 |
DisclosureSEC source: 0001282304-21-000008 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,178 Read SEC document |
| May 14, 2021 Filed May 17, 2021 21:26 UTC | CEL SCI CORP CVM · Entity 7495 | GrantOptions · Derivative | 160,000 | $0.01 Strike: $20.61 | $1,600.00 |
DisclosureSEC source: 0001236215-21-000007 · primary_doc.xml · derivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 703,253 Underlying: Common Stock · 160,000 shares Expires 2031-05-13 F1 · derivative.exercise_date: Each option entitles the holder to purchase one share of the Company's common stock at a price of $20.61 per share. The stock options vest 100% upon either (a) the filing of the first marketing application for any pharmaceutical based upon the Company's Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia, or (b) if the closing price of the Company's common stock exceeds $42.00 for one trading day. None of the options will be exercisable before May 13, 2022. Read SEC document |
| March 31, 2021 Filed Apr 1, 2021 14:13 UTC | CEL SCI CORP CVM · Entity 7495 | GrantCommon Stock | 248 | $15.21 | $3,772.08 |
DisclosureSEC source: 0001646989-21-000005 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,743 Read SEC document |
| December 31, 2020 Filed Jan 4, 2021 14:11 UTC | CEL SCI CORP CVM · Entity 7495 | GrantCommon Stock | 309 | $11.66 | $3,602.94 |
DisclosureSEC source: 0001236031-21-000004 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,495 Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 13:40 UTC | CEL SCI CORP CVM · Entity 7495 | GrantCommon Stock | 275 | $12.75 | $3,506.25 |
DisclosureSEC source: 0001236031-20-000031 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,186 Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 14:40 UTC | CEL SCI CORP CVM · Entity 7495 | GrantCommon Stock | 228 | $14.92 | $3,401.76 |
DisclosureSEC source: 0001236031-20-000027 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,911 Read SEC document |
| April 20, 2020 Filed Apr 20, 2020 20:55 UTC | CEL SCI CORP CVM · Entity 7495 | GrantOptions · Derivative | 160,000 | $0.01 Strike: $10.93 | $1,600.00 |
DisclosureSEC source: 0001236031-20-000020 · primary_doc.xml · derivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 544,453 Underlying: Common Stock · 160,000 shares Expires 2030-04-19 F1 · derivative.exercise_date: These stock options are performance based. Each option entitles the holder to purchase one share of the Company's common stock at a price of $10.93 per share. The stock options vest upon the achievement of the following performance goals: i) 25% of the options will vest when the closing price of the Company's common stock exceeds $20.00 for ten consecutive trading days; ii) 50% of the options will vest when the closing price of the Company's common stock exceeds $25.00 for ten consecutive trading days; iii) 75% of the options will vest when the closing price of the Company's common stock exceeds $30.00 for ten consecutive trading days; and iv) 100% of the options will vest when either (a) the filing of the first marketing application for any pharmaceutical based upon the Company's Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia or (b) the closing price of the Company's common stock exceeds $40.00 for ten consecutive trading days. Read SEC document |
| March 31, 2020 Filed Apr 1, 2020 13:11 UTC | CEL SCI CORP CVM · Entity 7495 | GrantCommon Stock | 296 | $11.54 | $3,415.84 |
DisclosureSEC source: 0001236031-20-000015 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,683 Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 12:45 UTC | CEL SCI CORP CVM · Entity 7495 | PurchaseCommon Stock | 923 | $10.83 | $9,996.09 |
DisclosureSEC source: 0001236031-20-000008 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,387 F1 · shares: On February 26, 2020, Dr. Zimmerman purchased $10,000 worth of restricted stock directly from the Company at the closing price on February 26, 2020, the most recent closing price available. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 15:36 UTC | CEL SCI CORP CVM · Entity 7495 | GrantCommon Stock | 373 | $9.15 | $3,412.95 |
DisclosureSEC source: 0001236031-20-000004 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,464 Read SEC document |
| September 30, 2019 Filed Oct 1, 2019 20:44 UTC | CEL SCI CORP CVM · Entity 7495 | GrantCommon Stock | 382 | $8.94 | $3,415.08 |
DisclosureSEC source: 0001236031-19-000030 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,091 Read SEC document |
| September 04, 2019 Filed Sep 5, 2019 12:00 UTC | CEL SCI CORP CVM · Entity 7495 | GrantCommon Stock | 2,375 | $7.16 | $17,005.00 |
DisclosureSEC source: 0001236031-19-000025 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,302 Read SEC document |
| May 07, 2019 Filed May 8, 2019 12:09 UTC | CEL SCI CORP CVM · Entity 7495 | GrantCommon Stock | 4,373 | $6.86 | $29,998.78 |
DisclosureSEC source: 0001236031-19-000018 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,927 Read SEC document |
| April 11, 2019 Filed Apr 12, 2019 20:48 UTC | CEL SCI CORP CVM · Entity 7495 | GrantOptions · Derivative | 211,459 | $0.01 Strike: $5.65 | $2,114.59 |
DisclosureSEC source: 0001236031-19-000010 · primary_doc.xml · derivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,453 Underlying: Common Stock · 211,459 shares Expires 2029-04-10 F1 · shares: Part of the options were awarded in recognition of the salary that has been deferred over an approximate 12 month period and not paid in cash. These options awarded are equal to 0.25 option for every dollar deferred. F2 · derivative.exercise_date: The stock options vest in three (3) equal annual installments commencing one year after the grant date. Read SEC document |
| March 29, 2019 Filed Apr 1, 2019 15:55 UTC | CEL SCI CORP CVM · Entity 7495 | GrantCommon Stock | 965 | $3.54 | $3,416.10 |
DisclosureSEC source: 0001236031-19-000005 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,554 Read SEC document |
| December 31, 2018 Filed Jan 2, 2019 21:53 UTC | CEL SCI CORP cvm · Entity 7495 | SaleCommon Stock | 2,474 | $2.93 | $7,248.82 |
DisclosureSEC source: 0001236215-19-000002 · primary_doc.xml · nonDerivative · entry 2 ZIMMERMAN DANIEL H · CIK 0001236028 · Sr. Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,589 Read SEC document |
| December 31, 2018 Filed Jan 2, 2019 21:53 UTC | CEL SCI CORP cvm · Entity 7495 | GrantCommon Stock | 1,190 | $2.87 | $3,415.30 |
DisclosureSEC source: 0001236215-19-000002 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Sr. Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,063 Read SEC document |
| September 28, 2018 Filed Oct 1, 2018 14:44 UTC | CEL SCI CORP CVM · Entity 7495 | GrantCommon Stock | 843 | $4.05 | $3,414.15 |
DisclosureSEC source: 0001236031-18-000041 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,873 Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 18:19 UTC | CEL SCI CORP CVM · Entity 7495 | GrantCommon Stock | 84,337 | $0.83 | $69,999.71 |
DisclosureSEC source: 0001236031-18-000034 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,030 Read SEC document |
| June 29, 2018 Filed Jul 2, 2018 15:04 UTC | CEL SCI CORP CVM · Entity 7495 | GrantCommon Stock | 3,713 | $0.92 | $3,415.96 |
DisclosureSEC source: 0001236031-18-000031 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,693 Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:41 UTC | CEL SCI CORP CVM · Entity 7495 | GrantOptions · Derivative | 100,000 | $0.01 Strike: $2.45 | $1,000.00 |
DisclosureSEC source: 0001236031-18-000019 · primary_doc.xml · derivative · entry 2 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,694 Underlying: Common Stock · 100,000 shares Expires 2028-04-30 F2 · derivative.exercise_date: The stock options vest in three (3) equal annual installments commencing one year after the grant date. Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:41 UTC | CEL SCI CORP CVM · Entity 7495 | GrantOptions · Derivative | 26,194 | $0.01 Strike: $2.45 | $261.94 |
DisclosureSEC source: 0001236031-18-000019 · primary_doc.xml · derivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,694 Underlying: Common Stock · 26,194 shares Expires 2028-04-30 F1 · shares: The options were awarded in recognition of the salary that has been deferred over the last 18 months and not paid in cash. The options awarded are equal to 0.25 option for every dollar deferred. F2 · derivative.exercise_date: The stock options vest in three (3) equal annual installments commencing one year after the grant date. Read SEC document |
| March 30, 2018 Filed Apr 3, 2018 14:00 UTC | CEL SCI CORP CVM · Entity 7495 | GrantCommon Stock | 2,422 | $1.41 | $3,415.02 |
DisclosureSEC source: 0001236031-18-000012 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,980 Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 15:19 UTC | CEL SCI CORP cvm · Entity 7495 | GrantCommon Stock | 1,807 | $1.89 | $3,415.23 |
DisclosureSEC source: 0001236031-18-000004 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Sr. Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,558 Read SEC document |
| September 29, 2017 Filed Oct 2, 2017 14:31 UTC | CEL SCI CORP cvm · Entity 7495 | GrantCommon Stock | 2,058 | $1.66 | $3,416.28 |
DisclosureSEC source: 0001236215-17-000013 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Sr. Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,751 Read SEC document |
| September 18, 2017 Filed Oct 2, 2017 14:31 UTC | CEL SCI CORP cvm · Entity 7495 | GrantOptions · Derivative | 20,000 | $1.59 Strike: $1.59 | $31,800.00 |
DisclosureSEC source: 0001236215-17-000013 · primary_doc.xml · derivative · entry 2 ZIMMERMAN DANIEL H · CIK 0001236028 · Sr. Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,668 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.expiration_date: The stock options vest in three(3) equal annual installments commencing one year after the grant date. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 14:39 UTC | CEL SCI CORP cvm · Entity 7495 | GrantCommon Stock | 1,532 | $2.23 | $3,416.36 |
DisclosureSEC source: 0001236215-17-000009 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Sr. Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,693 Read SEC document |
| June 29, 2017 Filed Jun 30, 2017 20:50 UTC | CEL SCI CORP cvm · Entity 7495 | GrantOptions · Derivative | 6,000 | $0.01 Strike: $1.87 | $60.00 |
DisclosureSEC source: 0001236031-17-000009 · primary_doc.xml · derivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,968 Underlying: Common Stock · 6,000 shares Expires 2027-06-28 F1 · derivative.exercise_date: The stock options vest in three (3) equal annual installments commencing one year after the grant date. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 14:10 UTC | CEL SCI CORP cvm · Entity 7495 | GrantCommon Stock | 39,911 | $0.09 | $3,416.38 |
DisclosureSEC source: 0001236031-17-000004 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,023 Read SEC document |
| December 30, 2016 Filed Jan 3, 2017 15:46 UTC | CEL SCI CORP cvm · Entity 7495 | GrantCommon Stock | 46,026 | $0.07 | $3,083.74 |
DisclosureSEC source: 0001236215-17-000004 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Sr. Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,112 Read SEC document |
| September 30, 2016 Filed Oct 3, 2016 17:14 UTC | CEL SCI CORP CVM · Entity 7495 | GrantCommon Stock | 11,388 | $0.30 | $3,416.40 |
DisclosureSEC source: 0001236031-16-000046 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,086 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.